3 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMOCompleted
Primary Objective: The primary objective of this study is to assess lung volume measured by EIT and minute ventilation measured by the ventilator during CMV and FCV at the ICU. This will allow for an adequate powercalculation for future studies.…
Approved WMOCompleted
Primary• To evaluate the safety and tolerability of AMG 910 in adult subjects. • To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Secondary• To characterize the PK of AMG 910• To evaluate preliminary anti-tumor…